35 results about "Chloromandelic Acid" patented technology

The invention discloses a novel carbonyl reductase, a gene, a mutant thereof, a recombinant expression vector containing the gene and the mutant, a recombinant expression transformant, a recombinase preparation method, and applications of the carbonyl reductase and recombinase to preparation of active chiral alcohols with a chiral carbonyl compound before asymmetrical reduction. The carbonyl reductase is derived from candida glabrata, is applied to preparation of a plurality of optically-active chiral alcohols such as (R)-chloromandelic acid methyl ester, (R)-2-hydroxy-4-phenyl ethyl butyrate, (R)-4-chlorin-3-phenyl ethyl butyrate and the like. Compared with other preparation methods, a product prepared through the method has high concentration, does not require additionally or slightly adding any expensive coenzyme, has high optical purity, and has the advantages of mild reaction conditions, easiness and convenience for operating, easiness for amplifying and the like, and has a good industrial application prospect in the production of clopidogrel, L-carnitine and perindopril antihypertensive medicinal intermediates.

The invention relates to a carbonyl reductase CgKR1 mutant, a coding gene of the mutant, a recombinant expression vector containing the gene of the carbonyl reductase mutant, a recombinant expression transformant, a recombinase, a preparation method of the recombinase, and an application of the carbonyl reductase mutant to asymmetric reduction of ketonic ester for preparation of optically pure chiral hydroxyl ester, such as catalysis of o-cyano methyl phenylglyoxylate for asymmetric reduction to prepare (R)-o-chloro mandelic acid methyl ester. Compared with wild enzymes, the carbonyl reductase mutant has the advantages that the thermal stability is substantially improved, and the catalytic activity of part of the mutant to the o-chlorobenzoic acid formyl methyl ester is also obviously improved. The multiple mutants can be applied to catalysis of the ketonic ester for asymmetric reduction to prepare the optical purely-chiral hydroxyl ester, such as catalysis of the o-cyano methyl phenylglyoxylate for asymmetric reduction to prepare the optically pure (R)-o-chloro mandelic acid methyl ester. The carbonyl reductase mutants have the very good industrial application prospect.

The invention relates to a method for preparing clopidogrel. The conventional synthetic methods have the disadvantages of poor environmental protection, disadvantageous industrial production, low optical purity of final products and high cost. The technical scheme adopted by the invention comprises the following steps of: performing a reaction on a compound, namely, R,S-o-chloromandelic acid and methanol to produce R,S-chloromandelic acid methyl ester; performing the reaction on the R,S-chloromandelic acid methyl ester and benzene sulfonyl chloride under the action of an alkaline catalyst to produce 2-benzenesulfonic acyloxy-2(2-chlorphenyl) methyl acetate; performing an SN2 substitution reaction on the 2-benzenesulfonic acyloxy-2(2-chlorphenyl) methyl acetate and 4,5,6,7-tetrahydro-thiophene pyridine hydrochloride under an alkaline condition to produce R,S-clopidogrel free alkali; resolving the R,S-clopidogrel free alkali in resolving solvent by using a resolving agent; and dissociating the resolved R,S-clopidogrel free alkali to prepare the clopidogrel. In a synthetic route of the invention, reaction conditions are temperate, used reaction substrates are environmentally friendly, reaction yield in each step is high, the optical purity of a final product is up to over 99.5 percent, and pollution-free production can be realized.

The invention provides a method for producing R-mandelic acid and derivates thereof by biocatalysis. The method comprises performing hydrolysis reaction in a reaction system which takes racemization mandelonitrile compound shown in formula (I) as the zymolyte, and nitrilase obtained by culturing bacillus foecalis alkaligenes (CCTCC No: M 208168) as the catalyst at 20-60 DEG C with pH being 8.0-8.5 to obtain chiral R-mandelic acid and derivates thereof shown in corresponding formula (II). The invention has the beneficial effects that the activity of strain bacillus foecalis alkaligenes is high, the dosage of thallus is little, the produced waste water in the reaction process is little, and pollution is less; the reaction conditions are mild and energy consumption is low; the cost is low, conversion rate is high and yield is high, and the invention is favorable for industrialized production of chiral R-mandelic acid and R-chloro mandelic acid.

The invention discloses a novel chiral resolving agent S-(1) which is used for chemically resolving (RS)-chloromandelic acid to prepare the (R)-chloromandelic acid. The invention further discloses a preparation method of the (R)-chloromandelic acid. The preparation method comprises the following steps: making the resolving agent S-(1) react with the (RS)-chloromandelic acid to obtain a (R)-chloromandelic acid and resolving agent diastereomer salt, decomposing the (R)-chloromandelic acid and resolving agent diastereomer salt to obtain the (R)-chloromandelic acid, and optionally recovering the S-(1). The preparation method has the beneficial effects that (1), the chiral resolving agent (S)-1 is high in resolving efficiency, stable in chemical property, and easy to separate and recycle, and the recycling purity is more than 99 percent; (2), an industrial line of the preparation method is developed, the process condition is mild, and industrialized production is facilitated; (3), the content of the prepared (R)-chloromandelic acid is more than 99 percent, and the ee value is more than 99 percent; (4), the used organic solvent can be recycled, and no special and toxic reagents are used.

The present invention relates to an improved preparation method of ortho-chloro-mandelic acid. Said method uses ortho-chlorobenzaldehyde and chloroform as raw material, and adopts the following steps: under the action of concentrated alkali and phase-transfer catalyst making the raw materials fully react, using ethyl acetate to make extraction, then removing ethyl acetate, adding alkali and water, using toluene to extract and remove impurities from aqueous solution of sodium ortho-chloromandelate, making acidification, using ethyl acetate to make extraction and using toluene to make crystallization, so that adopting one-kettle process to prepare ortho-chloromandelic acid.

The invention relates to an extraction method for a chiral medical intermediate, in particular to a separation extraction method for (R)-2-chloromandelic acid. The method at least comprises the following steps that strongly-alkaline anion resin is pretreated, wherein pretreatment comprises the steps of alkaline washing and acid washing in sequence, and quaternary ammonium salt strongly-alkaline anion resin is preferably selected as the strongly-alkaline anion resin; the treated strongly-alkaline anion resin is adopted for adsorbing a to-be-treated solution of the (R)-2-chloromandelic acid; anelution agent is adopted for elution, an eluent is obtained, extracted and concentrated, and the (R)-2-chloromandelic acid is obtained. The separation extraction method has a good separation effect and is high in yield, the adopted strongly-alkaline anion resin is long in service life, the separated water-phase system can continue to provide the reaction system for the next biological catalysis, the production cost is reduced, and discharge of waste water is reduced.

The invention discloses a preparation method of clopidogrel hydrogen sulfate type II. According to the method, clopidogrel hydrogen sulfate type II is prepared by taking clopidogrel free alkali as a raw material, and a preparation method of clopidogrel free alkali comprises the following steps: (1) preparing a reaction mixed solution of R-chloromandelic acid methyl ester by the reaction of R-chloromandelic acid and methanol in an organic solvent and in the presence of a catalyst; (2) mixing the reaction mixed solution of R-chloromandelic acid methyl ester with an organic base and a catalyst, reacting in the presence of benzenesulfonyl chloride to obtain a reaction mixed solution of methyl 2-benzenesulfonyl-2-chlorophenylacetate; (3) mixing the reaction mixed solution of methyl 2-benzenesulfonyl-2-chlorophenylacetate obtained in the step (2) with 4,5,6,7-Tetrahydrothieno[3,2,c] pyridine hydrochloride and potassium carbonate for reaction to obtain the clopidogrel free alkali. According to the method, the solvent does not need to be supplemented in the last two steps, the solvent is directly used, and the reaction liquid concentration time is saved.

The invention provides a preparation method of optically pure 2-chloromandelic acid, which comprises the following steps: A) adding a chiral resolving agent, 2-chloromandelic acid and metallic compound into a solvent, dissolving by heating, cooling while stirring, carrying out vacuum filtration after a solid precipitates, drying and collecting the solid, wherein the mol ratio of chiral resolving agent to 2-chloromandelic acid is 1:4-2:1, and the mol ratio of metallic ion to 2-chloromandelic acid in the metallic compound is 1:4-2:1; and B) after recrystallizing the solid obtained in the step A), regulating the pH value to 1-2 with an acid solution, carrying out vacuum filtration to recycle the undissolved substance, extracting the mother solution with an organic solvent, drying, and carrying out spin drying to obtain the optically pure 2-chloromandelic acid product. The technique is simple and convenient, the raw materials and the resolving agent are innoxious and accessible, and the resolving agent can be recycled, thereby lowering the preparation cost and being green and economical. Meanwhile, the method is beneficial to implementing industrial mass production, and can satisfy the demands of people.

The invention provides a biological synthesis method of (R)-o-chloromandelic acid. The biological synthesis method comprises the following steps: feeding o-chloromandelic nitrile into a converting solution, conducting reaction for 8-12h under the conditions that the pH is 7.0-9.0 and the temperature is 20-40 DEG C, stopping feeding, and continuing conducting reaction for 1-4h to obtain the (R)-o-chloromandelic acid, wherein the converting solution comprises MG nitrilase-containing E.coli engineering bacteria. The method, combining use of the MG nitrilase and feeding of the o-chloromandelic nitrile, is used for preparing the (R)-o-chloromandelic acid, so that the process route is simple, reaction conditions are mild, pollution is free, the accumulated concentration of the (R)-o-chloromandelic acid during a single-batch reaction is as high as 600mM, and the ee value is greater than 98%; therefore, the biological synthesis method has a good industrial application prospect.

The invention discloses a method used for separating and measuring 2-chloromandelic acid enantiomers via HPLC. The method comprises following steps: R-2-chloromandelic acid samples are subjected to separating measuring via HPLC, wherein in separating measuring, cellulose-tri-4-methyl benzoate_chiral chromatographic column is taken as a stationary phase chiral chromatographic column, a mixed solution of alkanes and low alcohols is taken as a mobile phase for isocratic elution. The method is capable of realizing separating and measuring 2-chloromandelic acid enantiomers simply, rapidly, and accurately.

The invention discloses a preparation method for an R-ortho-chloromandelic acid and an acyl compound thereof. According to the preparation method, racemic chlomandelic acid is adopted as the raw material, lipase is adopted as a biological separation catalyst, acidic resin is adopted as a racemic catalyst, p-chlorobenzenethiol phenolic ester is adopted as the acyl donor to carry out the dynamic kinetic resolution to obtain the acyl compound of the R-ortho-chloromandelic acid; LiOH is adopted for hydrolysis to obtain the R-ortho-chloromandelic acid. The preparation method is moderate in reaction condition, environment-friendly, high in product yield and high in selectivity, the adopted racemic catalyst is low in cost and easy to obtain, so that the preparation method has quite high application value in industrial production.

The invention relates to the field of biotechnology and especially relates to a method for preparing R-o-chloromandelic acid by using nitrilase engineering bacteria. The method comprises carrying out centrifugation on a culture liquid obtained by fermental cultivation of engineering bacteria containing recombinant nitrilase genes, carrying out a conversion reaction process on o-chloromandelonitrile as a substrate and a buffer solution as a reaction medium in the presence of wet bacteria as catalysts, and after the reaction, carrying out separation purification on the reaction product mixed liquid to obtain R-o-chloromandelic acid, wherein the engineering bacteria containing recombinant nitrilase genes are constructed by nucleotide sequence coding genes shown in the formula SEQ ID NO. 2. The method has a fast reaction rate and a high reaction conversion rate.

The invention belongs to the field of pharmaceutical chemistry and particularly relates to a preparation method of (R)-chloromandelic acid. The preparation method at least comprises the following steps: culturing engineered escherichia coli expressing nitrilase, taking the engineered escherichia coli as a catalyst, chloromandelonitrile as a substrate and a reaction buffer as a reaction medium forreaction, separating and collecting supernate after the reaction is finished, obtaining flow-through liquid after extracting (R)-chloromandelic acid from the supernate, and recycling the flow-throughliquid as a reaction buffer for at least one time. According to the preparation method, a utilization ratio of the reaction buffer is increased, so that the production cost of (R)-chloromandelic acidis lowered; the emission of waste liquid is significantly reduced; and green and environment-friendly production of (R)-chloromandelic acid is achieved.

The invention discloses a preparing method of (R)-(-)-4-chloromandelic acid through resolution by taking (R)-(+)-1-(1-naphthyl)ethylamine as a chiral resolution agent. 4-chloromandelic acid and the chiral resolution agent (R)-(+)-1-(1-naphthyl)ethylamine react in a suitable alcohol solvent to generate (R)-(+)-1-(1-naphthyl)ethylamine salt of the 4-chloromandelic acid, by using different solubilities of an enantiomer salt, crystallizing and suction filtration are performed to obtain the (R)-(+)-1-(1-naphthyl)ethylamine salt of the (R)-(-)-4-chloromandelic acid, and after salt recrystallization, the (R)-(-)-4-chloromandelic acid can be obtained by acidizing; after the solution containing the (R)-(+)-1-(1-naphthyl)ethylamine is combined, alkalization treatment is performed, the resolution agent (R)-(+)-1-(1-naphthyl)ethylamine can be recycled. The preparing method has the characteristics of mild conditions, simple operation, good product yield and high optical purity. The resolution agent can be recycled for use, and is extremely suitable for industrial production of (R)-(-)-4-chloromandelic acid.

This patent describes a method for resolving 2-chloromandelic acid enantiomer by biocatalyst catalytic interesterification kinetics. Racemic 2-chloromandelic acid is resolved in an organic solvent medium by catalytic interesterification kinetics by utilizing high-catalytic efficiency and high-stereoselectivity lipase so as to obtain (S)-2-chloromandelic acid and (R)-acetyl-2-chloromandelic acid. The reaction system adopts an organic solvent as a reaction medium, greatly improves the thermal stability and the catalytic efficiency of the lipase, and greatly improves the substrate conversion rateand the optical activity, and the optical activity of the substrate is 98.15% or above. Compared with other resolving technologies, the method has the advantages of mild reaction conditions, simple operation and little environmental pollution, and can obtain the (S)-2-chloromandelic acid and (R)-acetyl-2-chloromandelic acid with high optical purity, and the (R)-acetyl-2-chloromandelic acid is used as a precursor of a key intermediate for synthesizing a chiral resolving agent and clopidogrel with high application prospect. The patent provides a feasible obtaining method.

Methanol and concentrated sulphuric acid are taken as solvent and 2-chloric mandelic acid is taken as raw material for esterification reaction, sodium hydroxide is added to be neutral after full reaction, reducing reaction is carried out with sodium borohydride, diluted hydrochloric acid is used for neutralization and water is added for dilution, distillation and extraction by 1, 2-dichloroethane are carried out to obtain 1-2-(2-chlorphenyl)-1, 2-ethylene glycol, then triethylamine and mesyl chloride are added into the 1-2-(2-chlorphenyl)-1, 2-ethylene glycol for esterification reaction, and then diluted hydrochloric acid, sodium bicarbonate and drinking water are respectively used for washing, reduced pressure distillation is carried out to remove solvent, so as to obtain sticky grease, ethyl acetate is added at the temperature below 77 DEG C for dissolution, heating is carried out until refluxing, temperature reduction, crystallization, centrifugation and drying are carried out, thus obtaining yellow solid 1-(2-chlorphenyl)-1, 2-glycol dimethyl sulphonate. Then dimethyl sulphoxide and potassium hydroxide are taken as raw materials, mixed liquid of 1-imidazoly acetonitrile, carbon disulphide and dimethyl sulphoxide is dropwise added for condensation reaction, mixed liquid of dimethyl sulphoxide and 1-(2-chlorphenyl)-1, 2-glycol dimethyl sulphonate is dropwise added for ring formation reaction, and ice analysis, extraction by ethyl acetate and reduce pressure distillation are carried out, thus obtaining E / Z-alpha-[4-(2-chlorphenyl)-1, 3-dithiolane-2-subunit]-1H-imidazolyl acetonitrile. The E / Z-alpha-[4-(2-chlorphenyl)-1, 3-dithiolane-2-subunit]-1H-imidazolyl acetonitrile is separated by silicagel column and then added with active carbon, distillation is carried out to remove most solvent, hot pressing filtering, temperature reduction, crystallization, centrifugation and drying are carried out, thus obtaining almost white or white lanoconazole powder solid.

The invention discloses a high-efficient composite powder-shaped sewage treating agent for desizing waste water and preparation method of the high-efficient composite powder-shaped sewage treating agent. The sewage treating agent comprises tartaric acid, ursodesoxycholic acid, 2- chloromandelic acid, calcium sulfate, magnesium carbonate, calcium carbonate, ferric trichloride, calcium oxide, sodium borate. The method is to orderly and evenly mix above matters. Compared with the prior art, the treating agent treats the desizing sewage containing 1-10 g / l PVA, wherein the COD (chemical oxygen demand) concentration of the desizing sewage reaches 5x104-10x104 mg / L, and chromaticity is 400 times; the removal rate reaches 80-85%, and recycle rate of PVA is 85-90%, and the chromaticity is 100 times below; the composite powder-shaped sewage treating agent is featured by wide adaptive temperature scale, good treatment effect, high recycle rate, and obvious decoloration.

The invention relates to a preparation method of lanoconazole, and belongs to the technical field of medicine synthesis. The invention aims to solve the problems of unstable reaction and low yield in the prior art. The invention provides a preparation method of lanoconazole, which comprises the following steps: by taking 2-chloromandelic acid as a raw material, firstly carrying out esterification reaction and chlorination reaction to synthesize an intermediate compound as shown in a formula II, and further carrying out reduction reaction on the compound as shown in the formula II in the presence of hydroboron to obtain a compound as shown in a formula III; in the presence of an acid applying agent, reacting the compound shown in the formula III with methylsulfonyl chloride to obtain a compound shown in a formula IV; the preparation method comprises the following steps: adding 1-imidazolyl acetonitrile, carbon dioxide and a phase transfer catalyst into a mixed solution of an organic solvent and water, adding a strongly alkaline potassium salt for reaction to obtain a reaction solution, adding a weakly alkaline buffer system into the reaction solution, then adding an intermediate compound shown as a formula IV for cyclization reaction, and after the cyclization reaction is finished, concentrating to remove the solvent and recrystallizing to obtain the compound shown as the formula IV. The corresponding product lanoconazole is obtained. The method has the effects of mild and stable reaction and high yield.

The invention discloses a method for synthesizing a novel uric acid lowering compound Arhalofenate intermediate. The novel uric acid lowering compound Arhalofenate intermediate is (R)-chloromandelic acid, and is prepared by the following specific synthetic steps: taking a common organic solvent as a resolution solvent, taking racemic chloromandelic acid as a raw material, taking (R)-amine as a resolving agent, performing reflux preparation to obtain (R)-amine*(R)-chloromandelic acid, adding an acid to regulate the pH value, repeatedly extracting with ethyl acetate, merging the organic phase, adding anhydrous sodium sulfate for drying, performing suction filtration and desalting, and performing reduced pressure drying, thereby obtaining the (R)-chloromandelic acid with high optical purity.The method disclosed by the invention has the beneficial effects that the synthetic method is readily available in raw materials, excellent in separating speed and effect, high in resolution rate, lowin cost, simple and convenient in operation, low in requirements on production conditions and equipment and easy for industrial production.